Loading...
XSEST14
Market cap3.80bUSD
Dec 20, Last price  
2.18USD
1D
-0.46%
1Q
5.31%
Jan 2017
149.14%
Name

Tianjin Zhongxin Phrmctl Gp Cp Ltd

Chart & Performance

D1W1MN
XSES:T14 chart
P/E
13.86
P/S
1.68
EPS
1.15
Div Yield, %
45.83%
Shrs. gr., 5y
-0.01%
Rev. gr., 5y
5.07%
Revenues
8.22b
-0.33%
2,115,756,0002,517,141,0002,149,968,0002,258,414,0002,365,338,0002,880,863,2603,473,471,2664,391,889,1475,129,925,9876,010,136,7287,086,879,2787,080,552,2386,178,821,7965,689,242,4966,358,622,3186,993,881,6976,603,652,0156,907,544,2568,249,249,5658,222,311,849
Net income
987m
+14.49%
64,032,00080,787,000-377,764,000-72,819,000182,080,000257,817,625293,287,101247,649,856441,299,096351,794,374357,800,340451,442,939422,423,006476,079,838561,679,706625,568,681661,704,350769,144,377861,793,906986,707,377
CFO
688m
+1.66%
10,496,000261,906,000-28,083,00020,131,000155,768,00083,407,791139,035,377173,880,27720,808,888213,435,404286,854,209360,583,419419,901,9090350,144,366495,488,678671,420,832852,401,231677,245,078688,487,880
Dividend
Jul 02, 20240.03272458 USD/sh
Earnings
May 15, 2025

Profile

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited, together with its subsidiaries, produces and sells traditional Chinese medicine, western medicine, and healthcare products primarily in the People's Republic of China. It operates in Chinese Medicine and Western Medicine segments. The company is also involved in the manufacture and sale of Chinese and western pharmaceutical and biological products; wholesale and retail sale of medicines, biochemical pharmaceutical products, and daily use products; and operation of hospitals. In addition, it provides logistics, stocks, equipment installation, and medicine processing services; medicine inspection and testing services; and pharmaceutical consultancy services. The company sells its medicinal products under its own brand to the wholesalers; and purchases medicinal products under other brands from distributors and sells these to other wholesalers. The company was formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited and changed its name to Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited in May 2022. Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited was incorporated in 1992 and is based in Tianjin, the People's Republic of China.
URL
http://www.zhongxinp.com/
IPO date
Jun 06, 2001
Employees
4,913
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
8,222,312
-0.33%
8,249,250
19.42%
6,907,544
4.60%
Cost of revenue
6,973,262
7,158,181
5,956,516
Unusual Expense (Income)
NOPBT
1,249,050
1,091,069
951,028
NOPBT Margin
15.19%
13.23%
13.77%
Operating Taxes
126,658
106,931
85,929
Tax Rate
10.14%
9.80%
9.04%
NOPAT
1,122,392
984,138
865,099
Net income
986,707
14.49%
861,794
12.05%
769,144
16.24%
Dividends
(859,149)
(386,722)
(231,973)
Dividend yield
3.31%
1.71%
0.96%
Proceeds from repurchase of equity
(22,665)
1,422
BB yield
0.09%
-0.01%
Debt
Debt current
81,800
105,735
31,597
Long-term debt
246,520
153,042
3,143
Deferred revenue
2
59,876
59,147
Other long-term liabilities
100,831
50,729
54,423
Net debt
(2,699,860)
(3,439,310)
(3,011,950)
Cash flow
Cash from operating activities
688,488
677,245
852,401
CAPEX
(140,928)
Cash from investing activities
(744,213)
Cash from financing activities
(836,649)
FCF
928,660
1,610,162
552,345
Balance
Cash
2,145,507
2,882,524
2,283,181
Long term investments
882,673
815,564
763,509
Excess cash
2,617,065
3,285,626
2,701,313
Stockholders' equity
5,793,689
5,669,537
5,309,522
Invested Capital
4,454,581
3,437,984
3,915,177
ROIC
28.44%
26.77%
23.07%
ROCE
17.64%
16.21%
14.36%
EV
Common stock shares outstanding
770,865
776,391
768,873
Price
33.65
15.64%
29.10
-7.35%
31.41
79.28%
Market cap
25,939,612
14.81%
22,592,975
-6.45%
24,150,303
79.28%
EV
23,284,298
19,184,158
21,287,705
EBITDA
1,379,179
1,207,628
1,066,562
EV/EBITDA
16.88
15.89
19.96
Interest
35,853
10,269
2,937
Interest/NOPBT
2.87%
0.94%
0.31%